If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
The Singapore Tourism Board (STB) is the statutory board under the Ministry of Trade and Industry which is tasked with the promotion of the country's tourism industry. In August 2017 the STB and the Economic Development Board (EDB) unveiled a unified brand, Singapore – Passion Made Possible, to market Singapore internationally for tourism and business purposes. The Orchard Road district, which contains multi-storey shopping centres and hotels, can be considered the centre of shopping and tourism in Singapore. Other popular tourist attractions include the Singapore Zoo, River Wonders, Bird Paradise and Night Safari (located in Northern Singapore). The Singapore Zoo has embraced the open zoo concept whereby animals are kept in enclosures, separated from visitors by hidden dry or wet moats, instead of caging the animals, and the River Wonders has 300 species of animals, including numerous endangered species. Singapore promotes itself as a medical tourism hub, with about 200,000 foreigners seeking medical care there each year. Singapore medical services aim to serve at least one million foreign patients annually and generate US$3 billion in revenue. In 2025, Singapore saw a record number of nearly 245 million people crossing its borders. In the same year, Singapore turned away more than 45,000 foreigners – 38% higher than 2024. Luxury Hotels in Singapore include Raffles Hotel, Marina Bay Sands, Grand Hyatt Singapore, Capella Singapore, Conrad Singapore, Hilton Singapore Orchard, Shangri-La Singapore and The Ritz-Carlton Millenia Singapore.
=== Treatment === Gastrointestinal surgery can often be performed in the outpatient setting. In the United States in 2012, operations on the digestive system accounted for 3 of the 25 most common ambulatory surgery procedures and constituted 9.1 percent of all outpatient ambulatory surgeries.
Glutamate-5-semialdehyde is a non-proteinogenic amino acid involved in both the biosynthesis and degradation of proline and arginine (via ornithine), as well as in the biosynthesis of antibiotics, such as carbapenems. It is synthesized by the reduction of glutamyl-5-phosphate by glutamate-5-semialdehyde dehydrogenase. In solution in water, the aldehyde is in chemical equilibrium with (S)-1-pyrroline-5-carboxylic acid and this is the form in which many of its biochemical reactions occur.
The Great Zimbabwe Bird first appeared in an armorial sense when it was incorporated in the coat of arms of Southern Rhodesia, which were granted by Royal Warrant on 11 August 1924. It was first used on a national flag when the full arms were displayed on the Rhodesian flag that was adopted on 11 November 1968. It then appeared alone on the Zimbabwe Rhodesian flag of 1979, and it is now displayed on the flag of Zimbabwe. The arms of 1924 were initially retained by the Zimbabwean Government until a new coat of arms were adopted on 12 September 1981. The Zimbabwe Bird depicted on the flag is rendered in the same format as it appeared on the arms of 1924 and as it appeared on the Rhodesian flag of 1968 and the Zimbabwe Rhodesian flag of 1979. The red star on which the bird is placed is a regular star. However, a different, rather flattened version of the bird, sometimes displayed on an irregular, flattened star, is often seen on flags that are manufactured outside of Zimbabwe. The origin of this discrepancy appears to be an illustration of the proposed new flag that was first released by the Zimbabwe Ministry of Information in April 1980, just prior to the country attaining full independence. This illustration showed the bird in a flattened version positioned over an irregular star.
Sources: en.wikipedia.org
=== RNA polymerase II === Proline isomerization of certain prolines in RNA polymerase II is key in the process of recruiting and placing processing factors during transcription. PPIases target RNA polymerase II by interacting with the Rpb1 carboxy terminal domain, or CTD. Proline isomerization is then used as part of the mechanism of the CTD to recruit co-factors required for co-transcriptional RNA processing, regulating RNA polymerase II activity. Nrd1 is a protein that is responsible for many of the transcriptional activities of RNAP II, specifically through the Nrd1- dependent termination pathway. This pathway requires the parvulin Ess1, or Pin1 depending on the organism, to isomerize the pSer5-Pro6 bond in the CTD. Without the cis conformation of the pSer5-Pro6 bond, created by Ess1/Pin1, Nrd1 cannot bind to RNAP II. Any variation from this process leads to a decrease in Nrd1 binding affinity, lowering the ability of RNAP II to process and degrade noncoding RNAs.
=== Expansion === In March 2020, many of the Cane's locations switched from dine-in to pick-up and take-out service only due to the COVID-19 pandemic, whereas others closed temporarily. As of July 2020, certain locations had reopened their dining rooms, although Graves said the company was in no rush to do so on a full scale. In 2021, in response to a shortage of workers at the time, the company began dispatching hundreds of its corporate employees to work in its restaurants as cooks and cashiers, in addition to their existing duties regarding the hiring of new employees. The company planned to hire 10,000 new employees. The company's co-CEO said that the corporate employees are trained in the kitchen and on the register under normal circumstances. In 2022, Raising Cane's sued a shopping center in Hobart, Indiana. After the restaurant chain had signed a long-term lease, it was revealed that the shopping center had a non-compete agreement with McDonald's which prohibited other vendors from selling de-boned chicken products in the complex. On June 27, 2023, Raising Cane's opened up their first New York location in Times Square.
== Major collections and examples == The world's fungal collections are concentrated in Europe and North America, although significant holdings exist elsewhere. Using data from Index Herbariorum, Thiers estimated that 15 to 20 million preserved fungal specimens exist across approximately 3,900 herbaria and fungaria worldwide. Historically, major fungaria were often housed within botanical institutes, plant-protection institutes, museums, and universities rather than existing as stand-alone institutions. Institutions listed in Index Herbariorum are assigned official acronyms, such as K and BPI, which are widely used in specimen numbering and in reference to collections.
=== Inreda AP === In collaboration with the Academic Medical Center in Amsterdam, Inreda Diabetic B.V. has developed a closed loop system with insulin and glucagon. The initiator, Robin Koops, started to develop the device in 2004 and ran the first tests on himself. In October 2016 Inreda Diabetic B.V. got the ISO 13485 license, a first requirement to produce its artificial pancreas. The product itself is called Inreda AP, and soon made some highly successful trials. After clinical trials, it received the CE marking, noting that it complies with European regulation, in February 2020. In October 2020 the health insurance company Menzis and Inreda Diabetic then started a pilot with 100 patients insured by Menzis. These are all patients that face very serious trouble in regulating their blood glucose levels. They now use the Inreda AP instead of the traditional treatment. Another large scale trial with the Inreda AP was set up in July 2021, and should determine whether Dutch health insurance should cover the device for all their insured. A smaller improved version of the Inreda AP is scheduled for release in 2023.
It was determined that this preparation behaved anomalously in certain immunoassays and was not suitable as an IS. Three different human pituitary extracts containing prolactin were subsequently obtained as candidates for an IS. These were distributed into ampoules coded 83/562, 83/573, and 84/500. Collaborative studies involving 20 different laboratories found little difference between these three preparations. 83/562 appeared to be the most stable. This preparation was largely free of dimers and polymers of prolactin. On the basis of these investigations, 83/562 was established as the Second IS for human prolactin. Once stocks of these ampoules were depleted, 84/500 was established as the Third IS for human prolactin. 84/500 has nearly run out and in 2016 replacement was proposed. The new 83/573 contains 67.2 mIU per ampoule when calibrated against the third IS and contains 1.002 g of human pituitary extract each (which is then lyophilized). Each ampoule contains approximately 3.2 μg of prolactin. The assigned value will be 67 mIU per ampoule. If a fifth IS is needed, it will likely be based on recombinant protein, as WHO has not received any further donations of human pituitary extracts.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.